Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 8.89 -2.95% -0.27
SYRS closed down 3.07 percent on Tuesday, March 2, 2021, on 73 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Mar 4
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical SYRS trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction -2.95%
NR7 Range Contraction -2.95%
Inside Day Range Contraction -2.95%
Wide Bands Range Expansion -2.95%
Oversold Stochastic Weakness -2.95%
Stochastic Buy Signal Bullish -5.93%
Lower Bollinger Band Walk Weakness -5.93%
Wide Bands Range Expansion -5.93%
Oversold Stochastic Weakness -5.93%
Lower Bollinger Band Walk Weakness 5.83%
Older End-of-Day Signals for SYRS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 22 hours ago
Down 2 % about 22 hours ago
Down 1% about 24 hours ago
Up 1% about 24 hours ago
60 Minute Opening Range Breakout 2 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Syros Pharmaceuticals, Inc. Description

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Diseases Disease Medication Acute Myeloid Leukemia Leukemia Myelodysplastic Syndrome Immune Mediated Diseases Acute Leukemia Refractory Acute Myeloid Leukemia

Is SYRS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.65
52 Week Low 4.26
Average Volume 799,941
200-Day Moving Average 10.39
50-Day Moving Average 11.61
20-Day Moving Average 10.94
10-Day Moving Average 9.86
Average True Range 1.04
ADX 18.91
+DI 17.26
-DI 27.99
Chandelier Exit (Long, 3 ATRs ) 10.34
Chandelier Exit (Short, 3 ATRs ) 11.34
Upper Bollinger Band 13.60
Lower Bollinger Band 8.28
Percent B (%b) 0.17
BandWidth 48.65
MACD Line -0.72
MACD Signal Line -0.45
MACD Histogram -0.2696
Fundamentals Value
Market Cap 419.63 Million
Num Shares 45.8 Million
EPS -1.95
Price-to-Earnings (P/E) Ratio -4.70
Price-to-Sales 34.40
Price-to-Book 7.62
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.86
Resistance 3 (R3) 9.94 9.78 9.74
Resistance 2 (R2) 9.78 9.60 9.74 9.71
Resistance 1 (R1) 9.47 9.49 9.39 9.39 9.67
Pivot Point 9.32 9.32 9.28 9.28 9.32
Support 1 (S1) 9.00 9.14 8.93 8.93 8.65
Support 2 (S2) 8.85 9.03 8.81 8.61
Support 3 (S3) 8.54 8.85 8.58
Support 4 (S4) 8.46